𧬠Metastatic Adenocarcinoma
Metastatic adenocarcinoma arises when glandular cancers spread to distant organs via blood or lymphatics.
β οΈ They account for a large proportion of metastatic tumours, complicating treatment and prognosis.
Early detection is critical.
π Common Primary Sources
- π« Lung: Spreads to liver, bones, brain, adrenals.
- 𦴠Thyroid: Papillary/follicular β lungs, bones.
- π½οΈ Gut: Oesophagus (Barrettβs), stomach, colorectal β liver, peritoneum.
- π©βπ¦° Ovarian/Uterine: Spread to peritoneum, lungs, liver, nodes.
- π©Ί Pancreas: Aggressive, late presentation β liver, peritoneum.
- ποΈ Breast: Ductal/lobular β bone, liver, lungs, brain.
- π§Ύ Adrenal/Parathyroid: Rare but can metastasize widely.
- π©Έ Renal cell carcinoma: (not classic adenocarcinoma but similar spread) β lungs, bones, liver, brain.
π« Common Cancers Not Typically Adenocarcinoma
- Bladder: Transitional cell carcinoma (TCC). Rare adenocarcinoma subtype exists.
- Larynx: Squamous cell carcinoma (SCC), smoking/alcohol related.
- Cervix: Mostly SCC (HPV-linked), though adenocarcinoma occurs in some cases.
π§ͺ Diagnostic Approach
- Biopsy & Histopathology: Gold standard, IHC to suggest tissue of origin.
- Imaging: CT, MRI, PET for mapping spread.
- Blood Markers: e.g., CA-125 (ovarian), CEA (colorectal), PSA (prostate differential).
π Treatment Options
- πͺ Surgery: Occasionally for isolated/oligometastatic disease.
- π Chemotherapy: Systemic therapy is cornerstone for widespread disease.
- π― Targeted Therapy: EGFR, ALK, HER2, KRAS inhibitors depending on mutation profile.
- β’οΈ Radiotherapy: Local control & symptom palliation (e.g., bone/brain mets).
- π‘οΈ Immunotherapy: Checkpoint inhibitors (e.g., PD-1/PD-L1 blockade) increasingly used in lung, GI, and renal adenocarcinomas.
π Clinical Pearls
- 𧬠Always consider **adenocarcinoma of unknown primary (CUP)** when biopsy shows glandular histology but no clear source.
- π‘ Lung, colorectal, pancreas, and breast are the most frequent culprits in adults.
- β οΈ Paraneoplastic syndromes may provide diagnostic clues (e.g., hypercoagulability in pancreatic adenocarcinoma).
- π§Ύ Prognosis depends on primary site, burden of metastases, and available targeted therapies.